Study on LM-24C5 for Advanced Solid Tumors

Sponsor: LaNova Medicines Limited

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT06187402

Provider View

This clinical trial is testing a new drug, LM-24C5, to determine its safety and the best dose for treating adults with advanced solid tumors that have not responded to standard treatments.

Patient Parameters

Program Overview

The purpose of this study is to evaluate the safety and tolerability of a new drug called LM-24C5 in adults with advanced solid tumors. Researchers aim to find the most effective dose for future studies. Participants will receive the drug and undergo various tests to monitor their health and response to the treatment.

Eligibility Criteria

Inclusion Criteria

  • Adults aged 18 or older who understand the study and agree to participate by signing a consent form.
  • Have a good overall health status with an ECOG performance score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
  • Expected to live at least 3 more months.
  • Have advanced solid tumors that have returned or not responded to standard treatments, or cannot tolerate available treatments.
  • Able to provide a tumor sample that meets study requirements.
  • Have at least one tumor that can be measured by scans.
  • Show good organ and bone marrow function in lab tests before starting the study.
  • Able to communicate well with the study team and follow study requirements.

Exclusion Criteria

  • Participated in another clinical trial within 28 days before starting this study.
  • Received any treatment targeting the study's investigational target.
  • Had cancer treatments like chemotherapy or radiotherapy within 21 days before starting this study.
  • Have not fully recovered from side effects of previous cancer treatments.
  • Have uncontrolled pain or cancer that has spread to the brain or spinal cord.
  • Have fluid buildup around the lungs, heart, or abdomen that needs frequent drainage.
  • Have severe allergic reactions to treatments containing monoclonal antibodies.
  • Are taking high doses of steroids or other immune-suppressing medications recently.
  • Have a history of autoimmune diseases or certain lung conditions.
  • Received live vaccines within 28 days before starting the study.
  • Are taking blood thinners for active blood clots.
  • Had major surgery or procedures within 28 days before starting the study.
  • Have severe heart disease or other uncontrolled illnesses.
  • Have a history of immune system deficiencies or organ transplants.
  • Have active infections like HIV, tuberculosis, hepatitis B or C.
  • Have other active cancers needing treatment.
  • Are pregnant, breastfeeding, or have a positive pregnancy test.
  • Have mental health conditions that may affect study participation.
  • Are deemed ineligible by the study investigator.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.